AC Immune SAの収益品質スコアはB+/52.749954です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
AC Immune SAはいつ収益を報告しますか?
AC Immune SAの次の収益報告は2026-07-29に予定されています
AC Immune SAの予想収益はいくらですか?
ウォール街のアナリストによると、AC Immune SAの予想収益は$275.47Kです。
AC Immune SAは収益予想を上回りましたか?
AC Immune SAの最近の収益は$1.11Mで、予想を打ち勝たない。
主要データ
前終値
$2.8
始値
$2.84
当日レンジ
$2.73 - $2.84
52週レンジ
$1.51 - $4
取引高
244.8K
平均取引高
314.1K
配当利回り
--
1株当たり利益(TTM)
-0.66
時価総額
$286.4M
ACIUとは何ですか?
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.